Biopharmaceutical Characterization Application Compendium - page 222

Africa
+43 1 333 50 34 0
Australia
+61 3 9757 4300
Austria
+43 810 282 206
Belgium
+32 53 73 42 41
Canada
+1 800 530 8447
China
800 810 5118
(free call domestic)
400 650 5118
Denmark
+45 70 23 62 60
Europe-Other
+43 1 333 50 34 0
Finland
+358 9 3291 0200
France
+33 1 60 92 48 00
Germany
+49 6103 408 1014
India
+91 22 6742 9494
Italy
+39 02 950 591
Japan
+81 45 453 9100
Latin America
+1 561 688 8700
Middle East
+43 1 333 50 34 0
Netherlands
+31 76 579 55 55
New Zealand
+64 9 980 6700
Norway
+46 8 556 468 00
Russia/CIS
+43 1 333 50 34 0
Singapore
+65 6289 1190
Spain
+34 914 845 965
Sweden
+46 8 556 468 00
Switzerland
+41 61 716 77 00
UK
+44 1442 233555
USA
+1 800 532 4752
©2013 Thermo Fisher Scientific Inc. All rights reserved. ISO is a trademark of the International Standards Organization.
All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. Specifications, terms and pricing are subject to change.
Not all products are available in all countries. Please consult your local sales representative for details.
Thermo Fisher Scientific,
San Jose, CA USA is
ISO 9001:2008 Certified.
BioPharma 2013_PN63946_E_11/13S
3
1186.1124 1186.1183 5.0
0.02
0
540
528.1921
0
540
528.1914
Conclusions
A CESI prototype was coupled to a Q Exactive mass spectrometer for the
characterization of two monoclonal antibodies at the peptide level.
CESI-MS was capable of analyzing very small (< 300 Da) and very large peptides
(>8000 Da) under same experimental conditions
100% sequence coverage achieved for each molecule with 1 single run &
1 enzymatic digest
High ionization efficiencies provided by CESI and highly sensitive MS
Allowed for in-depth analysis of glycosylations with relative abundance
varying more than 3 orders of magnitude
For Research Use Only. Not for use in diagnostic procedures.
All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries.
This information is not intended to encourage use of these products in any manners that might infringe the
intellectual property rights of others.
1...,212,213,214,215,216,217,218,219,220,221 223
Powered by FlippingBook